MedPath

Insulin Lispro

Generic Name
Insulin Lispro
Brand Names
Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
Drug Type
Biotech
CAS Number
133107-64-9
Unique Ingredient Identifier
GFX7QIS1II
Background

Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.

Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin lispro, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually cause cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after several oral medications such as Metformin, Gliclazide, or Sitagliptin have been tried, and when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.

Marketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as Insulin detemir, Insulin degludec, or Insulin glargine to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.

Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli and was the first commercially available insulin analog. Formerly called LYSPRO from the chemical nomenclature LYS(B28), PRO(B29), insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared to endogenous human insulin.

Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.

Indication

本品尤其适用于下列情况:

1.经常发生低血糖的1型糖尿病者,使用本品可减少低血糖的发生率;

2.生活不规律,外出活动较多的用胰岛素治疗的糖尿病患者,本品快速、短效的特点有助于及时调整胰岛素的用量。

Associated Conditions
Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Not Applicable
Completed
Conditions
Type 1 Diabetes
Interventions
First Posted Date
2012-06-18
Last Posted Date
2013-09-13
Lead Sponsor
University of Florida
Target Recruit Count
107
Registration Number
NCT01621776
Locations
🇺🇸

Camp Winona, DeLeon Springs, Florida, United States

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Phase 3
Completed
Conditions
Type 2 Diabetes
Chronic Kidney Disease
Interventions
First Posted Date
2012-06-18
Last Posted Date
2019-09-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
577
Registration Number
NCT01621178
Locations
🇺🇸

Academic Medical Research Institute, Los Angeles, California, United States

🇺🇸

Extended Arm Physician, Inc., Montgomery, Alabama, United States

🇺🇸

Infosphere, West Hills, California, United States

and more 44 locations

Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

Phase 4
Completed
Conditions
Gestational Diabetes Mellitus
Interventions
Drug: Insulin, Long-Acting and Insulin
First Posted Date
2012-06-07
Last Posted Date
2022-06-08
Lead Sponsor
Sansum Diabetes Research Institute
Target Recruit Count
40
Registration Number
NCT01613807

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Phase 4
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2012-02-06
Last Posted Date
2019-02-26
Lead Sponsor
Halozyme Therapeutics
Target Recruit Count
25
Registration Number
NCT01526733
Locations
🇺🇸

Profil Institute for Clinical Research, Chula Vista, California, United States

A Study in Participants With Type 1 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
First Posted Date
2011-11-30
Last Posted Date
2018-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
455
Registration Number
NCT01481779
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation

Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2011-11-18
Last Posted Date
2014-03-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
122
Registration Number
NCT01474538
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States

A Study in Participants With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2011-11-10
Last Posted Date
2018-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1369
Registration Number
NCT01468987
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom

A Study in Participants With Type I Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
First Posted Date
2011-10-18
Last Posted Date
2018-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1114
Registration Number
NCT01454284
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxford, United Kingdom

A Study in Adults With Type 1 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
First Posted Date
2011-08-22
Last Posted Date
2014-10-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
536
Registration Number
NCT01421147
Locations
🇷🇴

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

Phase 1
Completed
Conditions
Diabetes Mellitus Type 1
Interventions
First Posted Date
2011-04-13
Last Posted Date
2013-07-26
Lead Sponsor
Biodel
Target Recruit Count
13
Registration Number
NCT01334151
Locations
🇺🇸

Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States

© Copyright 2025. All Rights Reserved by MedPath